Fosun Pharma Reports Surge in Innovative Drug Revenue and R&D Investment in 2025Q3 Financial Results
Wednesday, October 29, 2025
On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), a leading Chinese pharmaceutical company, announced its financial results for the first three quarters of 2025, underscoring robust growth, a deepening R&D pipeline, and strengthened financial fundamentals. The conglomerate, which trades on both the Shanghai and Hong Kong stock exchanges, recorded operating revenue of RMB29,393 million, with net profit attributable to shareholders reaching RMB2,523 million for the nine months ended September 30, 2025. These results reflect its strategic push into innovative pharmaceuticals, with revenue from innovative drugs surpassing RMB6,700 million, representing an 18.09% year-on-year increase and indicating an ongoing transformation toward higher-value, innovation-driven operations.
Fosun Pharma’s performance is notably propelled by its investments in R&D and the successful commercialization of novel therapies. During the third quarter, Fosun launched several original products addressing critical therapeutic areas such as oncology and immune-inflammatory diseases. Notably, an additional indication for Fovinaciclib Citrate Capsules—Fosun's proprietary CDK4/6 inhibitor—was approved in China for adult patients with hormone receptor-positive, HER2-negative breast cancer, broadening treatment options for this patient group. Moreover, its self-developed denosumab injection, HLX14, secured regulatory green lights in the United States and EU—a landmark achievement for a China-originated denosumab product and an important step for global biopharma competitiveness by Asian innovators.
Beyond clinical and regulatory milestones, Fosun Pharma has strengthened its R&D leadership by advancing a diverse pipeline across radiopharmaceuticals, RNA therapeutics, gene therapy, and AI-driven drug research. Third-quarter R&D expenses reached RMB1,013 million, marking a near 29% increase year-on-year, while total nine-month R&D investment stood at RMB3,998 million. This aggressive allocation of resources is evident in pipeline programs such as HLX22 (a humanized anti-HER2 monoclonal antibody) and HLX43 (a PD-L1-targeted antibody-drug conjugate), the latter recently granted Orphan-Drug Designation by the US FDA for thymic epithelial tumors. Such recognition will support streamlined regulatory pathways, potentially accelerating market entry and benefiting patients with rare malignant diseases.
In September 2025, Fosun Pharma established a radiotherapy platform, Xingrui Jingxuan, tasked with integrated radiopharmaceutical diagnostic and therapy innovation for multiple cancer types. The subsidiary Henlius is spearheading global clinical trials, with over 400 patients enrolled for HLX43, reflecting commitment to international research collaboration and market reach. Fosun Pharma’s application for Brexucabtagene Autoleucel Injection (project code FKC889), aimed at relapsed/refractory B-cell precursor acute lymphoblastic leukemia, was also accepted by China’s NMPA during the quarter, supporting the company’s ambitions in advanced cell therapies.
Financially, Fosun Pharma achieved net operating cash flow of RMB3,382 million, up over 13% year-on-year, driven by disciplined supply chain management, asset-light business strategies, and enhanced operational efficiencies. In a significant capital markets achievement, the group completed both A-share and H-share repurchase plans and implemented new share incentive and restricted stock unit schemes to align management interests with long-term value creation. Additionally, Fosun issued RMB1 billion of medium-to-long-term Sci-Tech Innovation Bonds, marking the first such issuance by a private pharmaceutical enterprise in China following new regulatory support. The proceeds are aimed at accelerating R&D and innovative product launches.
Looking ahead, Fosun Pharma has reaffirmed its innovation-driven roadmap, vowing to continuously optimize R&D investments, expedite clinical development, and pursue strategic transformation across the pharmaceutical value chain. The group aims to bring higher-quality, more accessible healthcare solutions to patients in China and worldwide while setting new benchmarks for Asian biopharma industry advancement and global integration.
